Valneva SE
French biotechnology company
Valneva SE
| Type | Public |
|---|---|
| Key people | Thomas Lingelbach (CEO) |
| Industry | Biotechnology |
| Products | Vaccines |
| Website | [valneva.com Official website] |
Valneva SE is a French biotechnology company that specializes in the development and commercialization of vaccines for infectious diseases. The company was formed in 2013 through the merger of Vivalis SA and Intercell AG. Valneva is headquartered in Saint-Herblain, France.
History
Valneva was established in 2013 following the merger of two European biotechnology companies, Vivalis SA from France and Intercell AG from Austria. The merger aimed to create a leading company in the field of vaccines, leveraging the strengths of both companies in research and development.
Products
Valneva focuses on developing vaccines for infectious diseases with significant unmet medical needs. Some of the key products in Valneva's portfolio include:
- IXIARO: A vaccine for the prevention of Japanese encephalitis, a disease prevalent in Asia.
- DUKORAL: An oral vaccine for the prevention of cholera and traveler's diarrhea caused by Escherichia coli.
- VLA2001: A vaccine candidate for COVID-19, which is based on an inactivated virus platform.
Research and Development
Valneva invests heavily in research and development to expand its vaccine portfolio. The company collaborates with various organizations and governments to advance its vaccine candidates through clinical trials. Valneva's R&D efforts are focused on diseases such as Lyme disease, chikungunya, and Zika virus.
Collaborations and Partnerships
Valneva has established several partnerships to enhance its research capabilities and market reach. Notable collaborations include agreements with the U.S. Department of Defense for the development of a chikungunya vaccine and with Pfizer for the development of a Lyme disease vaccine.
Financial Performance
Valneva is publicly traded on the Euronext stock exchange. The company has experienced growth in revenue due to the successful commercialization of its vaccines and strategic partnerships.
Related pages
References
Ad. Transform your life with W8MD's
GLP-1 weight loss injections special from $29.99 with insurance
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
